Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease

Brian Bressler  1     Andres Yarur  2     Uri Kopylov  3     Marielle Bassel  4     Neil Brett  4     Trevor Lissoos  5     claudia lopez  5     Athanasios Natsios  6     Sumit Saha     Christina Kifnidi     Dirk Demuth     Haridarshan Patel     Gerassimos J. Mantzaris    
1 University of British Columbia,Vancouver,Canada
2 Medical College of Wisconsin,Milwaukee,United States
3 Chaim Sheba Medical Center,Ramat Gan,Israel
4 Evidera,Montreal,Canada
5 Takeda Pharmaceuticals USA Inc,Deerfield,United States
6 Takeda Hellas S.A.,Athen

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing